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1  |  INTRODUC TION
Traditional cancer treatment methods, including surgery, radiother-
apy, and chemotherapy, have progressed over recent years; however, 
there are still many limitations associated with these treatments 
such as the lack of selectivity between healthy and cancerous cells 
(Braun & Seymour, 2011; Brown & Giaccia, 1998). One approach 
being investigated to improve the selectivity of chemotherapy 
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Abstract
Directed enzyme prodrug therapy (DEPT) is a cancer chemotherapy strategy in which 
bacterial enzymes are delivered to a cancer site before prodrug administration, result-
ing	in	prodrug	activation	at	the	cancer	site	and	more	localized	treatment.	A	major	limi-
tation to DEPT is the poor effectiveness of the most studied enzyme for the CB1954 
prodrug,	NfnB	from	Escherichia coli, at concentrations suitable for human use. Much 
research	into	finding	alternative	enzymes	to	NfnB	has	resulted	in	the	identification	of	
the	Xenobiotic	reductases,	XenA	and	XenB,	which	have	been	shown	in	the	literature	to	
reduce environmentally polluting nitro-compounds. In this study, they were assessed 
for their potential use in cancer prodrug therapy strategies. Both proteins were cloned 
into	the	pET28a+	expression	vector	to	give	the	genetically	modified	proteins	XenA-his	
and XenB-his, of which only XenB-his was active when tested with CB1954. XenB-his 
was further modified to include a cysteine-tag to facilitate direct immobilization on 
to	a	gold	surface	for	future	magnetic	nanoparticle	DEPT	(MNDEPT)	treatments	and	
was named XenB-cys. When tested using high-performance liquid chromatography 
(HPLC),	XenB-his	and	XenB-cys	both	demonstrated	a	preference	for	reducing	CB1954	
at the 4-nitro position. Furthermore, XenB-his and XenB-cys successfully induced cell 
death in SK-OV-3 cells when combined with CB1954. This led to XenB-cys being iden-
tified	as	a	promising	candidate	for	use	in	future	MNDEPT	treatments.
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treatments is to direct the treatment to the cancer site, as is the case 
in directed enzyme prodrug therapy (DEPT) (Kratz, Müller, Ryppa, 
& Warnecke, 2008; Sinhababu & Thakker, 1996), which involves the 
delivery of a prodrug-activating enzyme to the cancer site before 
prodrug administration. Methods of directing prodrug-activating 
enzymes	 to	 solid	 tumors	 include	 antibodies	 (ADEPT)	 (Bagshawe,	
2006), genes (GDEPT) (Denny, 2001; Williams et al., 2015), viruses 
(VDEPT)	 (Chung-Faye	 et	 al.,	 2001;	 McNeish	 et	 al.,	 1998;	 Palmer	
et al., 2004; Race et al., 2007), and gold-coated magnetic nanoparti-
cles	(MNDEPT)	(Gwenin,	Gwenin,	&	Kalaji,	2009,	2011).
Bacterial	 nitroreductases	 (NTRs)	 are	 one	 type	 of	 prodrug-ac-
tivating enzyme used in DEPT strategies due to their ability to re-
duce the nitroaromatic prodrug CB1954 to its cytotoxic derivatives 
(Knox, Boland, et al. (1988); Knox, Friedlos, Jarman, & Roberts, 1988; 
McNeish	et	al.,	1998;	;	;	Knox,	Friedlos,	Marchbank,	&	Roberts,	1991;	








allowing the enzyme to reduce the prodrug to its active form (Chou 
&	Talalay,	1977;	Gwenin	et	al.,	2015;	Valiauga,	Williams,	Ackerley,	&	
Cenas, 2016; Zenno, Koike, Tanokura, & Saigo, 1996). The most heav-
ily	investigated	NTR	for	use	in	DEPT	strategies	is	the	NfnB	NTR	from	




larly upon reacting with cellular thioesters (Emptage, Knox, Danson, 
& Hough, 2009; Gwenin et al., 2015; Prosser et al., 2013; Race et al., 
2007).	The	low	turnover	rate	of	CB1954	by	NfnB	has	proven	to	be	
a significant limitation for this combination, so finding new ways to 
improve this clinical approach is of the utmost importance (Chung-
Faye et al., 2001; Gwenin et al., 2015; Searle et al., 2004).
Approaches	to	overcoming	the	limitations	of	the	NfnB/CB1954	
combination have included the development of other prodrugs 
with greater dose potency such as the hypoxia-activated prodrugs 
PR-104A	(Foehrenbacher	et	al.,	2013;	Guise	et	al.,	2010;	McKeage	
et al., 2011; Patterson et al., 2007; Singleton et al., 2009; Williams 
et	al.,	2015)	and	SN27686	(Singleton	et	al.,	2007)	or	the	identifica-
tion of other bacterial enzymes that operate in combination with the 
CB1954	prodrug	such	as	NfsA	from	E. coli (Copp et al., 2017; Vass 
et al., 2009), YfkO from Bacillus licheniformis (Emptage et al., 2009), 
or the novel nitroreductases from Bacillus cereus, BC_1619 and 
BC_3024, previously identified within our research group (Gwenin 
et al., 2015).
The	 two	 Xenobiotic	 reductases,	 XenA	 and	 XenB,	 from	
Pseudomonas putida (P. putida) have been identified from the litera-
ture	as	being	capable	of	reducing	a	nitro	(NO2) group, such as those 
found on explosive compounds like nitro-glycerin, in the presence of 
an	NADPH	cofactor	to	produce	an	NHOH	derivative	(Blehert,	Fox,	&	
Chambliss, 1999; Orville, Manning, Blehert, Fox, & Chambliss, 2004; 
Orville,	Manning,	Blehert,	Studts,	et	al.,	2004;	Pak	et	al.,	2000).	Like	
NfnB,	 the	 two	Xenobiotic	 reductases	are	 flavoproteins	but,	unlike	
NfnB,	which	is	a	dimeric	flavoprotein,	they	are	monomeric	flavopro-
teins (Orville, Manning, Blehert, Fox, et al., 2004; Orville, Manning, 
Blehert,	Studts,	et	al.,	2004).	While	the	ability	of	the	XenA	and	XenB	
enzymes to reduce to nitro groups in explosive compounds in the 
presence	of	NADPH	is	well	documented	within	the	literature,	their	
activity with nitroaromatic prodrugs such as CB1954 is yet to be 
established.
In this study, it was determined whether or not the two 
Xenobiotic reductases were able to readily reduce the CB1954 pro-
drug to its toxic metabolites to ascertain their potential for use in 
novel	MNDEPT	treatments.	Firstly,	for	the	ease	of	purification	and	
isolation, both Xenobiotic reductases were modified to contain a 
His-tag, and only the enzyme which showed reactivity toward the 
CB1954 prodrug, XenB, was then further modified to contain an 
N-terminal	 Cys-tag	 for	 immobilization	 onto	 gold-coated	 magnetic	
nanoparticles (Gwenin, Gwenin, & Kalaji, 2011) for possible use in 
MNDEPT.
2  |  MATERIAL S AND METHODS
2.1  |  Cloning of enzymes
Genomic	 DNA	 was	 isolated	 from	 P. putida using a Wizard® 
Genomic	DNA	Purification	kit	from	Promega.	The	primers	listed	in	
Table 1 were synthesized by Eurofins Genomics and used to amplify 
the xenA and xenB	genes	from	the	genomic	DNA	using	a	Techne	TC-
3000	thermocycler.	Amplification	of	the	xenA and xenB genes from 
genomic	DNA	was	achieved	using	PCR	set	up	using	thermic	cycling	
parameters under the following conditions; 98°C for 30 s, 15 cycles 
of 98°C for 10 s (denaturing), 68–58°C for 30 s (annealing), and 72°C 
for 30 s (extension). This was then followed by a final hold at 4°C. 
The PCR products were purified as previously described (Gwenin 
et al., 2015) using a GeneJet PCR purification kit and subjected to 






cessful ligation between the gene of interest and the plasmid vec-
tor, a PCR based on the T7 promoter and T7 terminator sequences, 
which flank the gene insert region contained within the vector, 
was	performed	using	Taq	DNA	Polymerase	Master	Mix	(Amplicon,	
Denmark). To amplify the recombinant plasmids, competent E. coli 
DH5α cells (200 µl) were transformed with a plasmid (~10 µl) and in-
cubated on agar plates containing Kanamycin (50 µg/ml). Kanamycin 
is used to select for bacterial colonies containing the pET28a+ plas-
mid with the KanR gene.
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2.2  |  Transformation
The transformation of recombinant plasmids containing the cloned 
xenA and xenB genes into E. coli	 Rosetta	 pLysS	 (Novagen,	Merck,	
UK) was done following the method described previously by Ball, 
Thompson,	Anderson,	Gwenin,	and	Gwenin	(2019).
2.3  |  Protein expression and purification
The expression and purification of all proteins used were done fol-
lowing the method previously described by Ball et al. (2019), with 
one	minor	modification.	In	this	work,	all	Lysogeny	Broth	media	used	
contained additional glucose (0.5%).
2.4  |  Enzyme reactivity with CB1954
The ability of the purified enzymes to reduce the CB1954 prod-
rug was confirmed following the method previously described 
by Gwenin et al. (2011). Briefly, the proteins were incubated with 
NADPH	 (300	μM) and CB1954 (100 μM) in phosphate buffer (PB) 
(50 mM, pH 7.2) and scanned using UV-visible spectroscopy every 
90 s for 15 min. For active enzyme/CB1954 combinations, product 
formation was measured at 420 nm (Gwenin et al., 2011, 2015).
2.5  |  CB1954 kinetics
All	 enzyme	 kinetics	 experiments	 were	 carried	 out	 following	 the	
method previously described by Ball et al. (2019), using a Thermo 
Scientific Varioscan 96-well plate microplate reader. The data were 
then transferred to SigmaPlot 12 (SPSS, Systat Software Inc.) where 
a non-linear regression tool was used to generate a Michaelis–
Menten hyperbolic curve and a report containing the important ki-




machine	 (Dionex	 Ultimate	 3000	 HPLC	 system,	 ThermoScientific,	
USA)	 using	 a	 C18	 column	 for	 analysis	 (Waters	 Spherisorb®	 5	 µm	
ODS2 4.6 mm × 250 mm C18 column, UK). The instrument was run 
using the following parameters: 50 µl injection volume, a fixed column 
oven temperate of 25°C, a run length of 45 min, and the UV wave-
length for detection was 420 nm (Ball et al., 2019; Gwenin et al., 2015).
2.7  |  Cell viability assays
Cell viability experiments were conducted using an MTT assay 
(Mosmann, 1983), following the method previously described by 
Gwenin	et	al.	 (2015).	Briefly,	SK-OV-3	cells	 (Sigma–Aldrich,	United	
Kingdom) were seeded at a density of 1000 cells per well, in 100 µl 
Dulbecco's Modified Eagles Medium (DMEM) containing 10% FBS 
and 1% penicillin/streptomycin and were allowed to attach overnight 
in a 5% CO2	incubator	at	37°C.	After	16	h,	the	medium	was	aspirated,	
and fresh medium (50 µl) containing CB1954 (20 µM) was added. 
Next,	 medium	 (50	 µl)	 containing	 the	 purified	 enzyme	 was	 added	
and after 4 h, the medium was removed, and cells were replenished 
with	complete	DMEM	(100	µl).	After	48	h,	20	µl	of	MTT	(5	mg/ml)	
was added to each well and incubated at 37°C for 4 h. The formazan 
crystals that formed were dissolved in 100 µl of DMSO, after remov-
ing the media carefully, and the absorbance was read at 570 nm in a 
Thermo Scientific Varioscan 96-well plate microplate reader.
3  |  RESULTS
3.1  |  Cloning and sequencing
Both the xenA and xenB genes were successfully amplified using 
PCR, purified, and inserted into the pET28a+ expression vector, 
which	adds	an	N-terminal	histidine	tag	(his-tag)	for	ease	of	protein	
purification. The recombinant plasmids containing the xenA and 
xenB genes were sequenced verified to confirm their identity before 
they were used in other experiments.
3.2  |  Protein expression and purification
The pET28a+ vector contains a his-tag that is added to all the re-
combinant proteins for ease of purification using metal ion affin-
ity	 chromatography	 (IMAC).	XenA-his	and	XenB-his	are	 the	native	
TA B L E  1   Primer	sequences	used	for	the	cloning	of	XenB	and	XenA






Note: The restriction enzyme cut site is in italics and underlined. The addition of the cysteine-tag is in bold and underlined.
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P. putida	XenA	and	XenB	cloned	into	the	pET28a+	vector.	The	XenB-
cys, however, was genetically modified using PCR to contain an ad-
ditional cysteine-tag (designed by our research group) (Gwenin et al., 
2011)	on	the	N-terminal	of	the	protein	which	is	6	amino	acids	long.	
The purpose of the cys-tag is to allow direct binding of the protein to 
metal surfaces such as gold. The additional weight of the amino acid 
tags	causes	small	changes	in	migration	on	the	SDS-PAGE	as	previ-
ously	described	(Gwenin	et	al.,	2011).	All	genetically	modified	pro-
teins were obtained at a yield of up to 5 mg/ml.
While	NTR	genes	express	a	homodimeric	flavoprotein	(Gwenin	
et	al.,	2015;	Parkinson,	Skelly,	&	Neidle,	2000)	(NfnB	monomer	unit	
approximately 26 kDa (Gwenin et al., 2015)), the Xenobiotic reduc-
tase genes express a monomeric flavoprotein (Orville, Manning, 
Blehert, Fox, et al., 2004; Orville, Manning, Blehert, Studts, et al., 
2004)	with	XenA	having	a	unit	size	of	roughly	39	(Orville,	Manning,	
Blehert, Studts, et al., 2004) kDa and XenB having a unit size of ap-
proximately 40 kDa (Orville, Manning, Blehert, Fox, et al., 2004).
3.3  |  Enzymatic reduction of the CB1954 prodrug
Initially, the reactivity of each enzyme with CB1954 in the presence 
of	an	NADPH	cofactor	was	tested	(Figure	1)	following	the	method	as	
previously described by V. Gwenin et al. (2011), Gwenin et al. (2015). 
For	 active	 enzyme/prodrug	 combinations,	 NADPH	 consumption	
was observed at 340 nm and the formation of the CB1954 hydroxy-
lamine products was seen at 420 nm.
XenB-his and XenB-cys both demonstrated the ability to re-
duce	 the	 CB1954	 using	 an	 NADPH	 cofactor;	 however,	 XenA-his	
showed	no	reactivity	with	CB1954.	To	test	the	NO2-reducing ability 
of	XenA-his	against	work	found	in	the	literature	(Yanto,	Yu,	Hall,	&	
Bommarius, 2010), it was tested again with a nitro-glycerin substrate 
and,	in	this	instance,	it	was	able	to	reduce	the	NO2 groups present in 
the	substrate.	It	was	postulated	that	the	XenA-his	enzyme	is	unable	
to reduce a nitroaromatic substrate such as CB1954, as literature 
has	also	shown	an	 inability	of	 the	XenA	enzyme	to	 reduce	 the	ni-
troaromatic	explosive	trinitrotoluene	(TNT)	in	a	similar	manner	(Pak	
et	al.,	2000),	 and	 it	was	decided	not	 to	 test	 the	XenA-his	enzyme	
any further at this stage, but to only proceed with the recombinant 
XenB-his and XenB-cys.
Thus, the Michaelis–Menten kinetic parameters were only deter-
mined for XenB-his and XenB-cys with respect to varying concen-
trations of CB1954 (Table 2).
When comparing the apparent Michaelis–Menten kinetic param-
eters obtained for XenB-his and XenB-cys reacting with CB1954, it 
appeared that the incorporation of the cysteine-tag has led to a de-
crease in the kinetic activity of the enzyme. XenB-cys demonstrated 
a lower turnover of CB1954 (Kcat = 1.8 s−1 compared to 8.2 s−1 for 
XenB-his) and a lower efficiency in its reaction with the prodrug 
compared to XenB-his (Kcat/Km = 0.0039 μM−1 S−1 compared to 
0.0049 μM−1 S−1 for XenB-his) despite having a much higher affinity 
for the prodrug (Km = 457 μM compared to 1690 μM for XenB-his). 
When	compared	to	the	kinetic	data	observed	when	testing	NfnB-his	
with the CB1954 prodrug, it is evident that both XenB-his and XenB-
cys demonstrate a superior affinity for the prodrug as they display 
a much lower value for Km (Km = 4064 μM	for	NfnB-his).	However,	
both XenB-his and XenB-cys were shown to be less efficient in their 
reaction	with	CB1954	 than	NfnB-his	 as	 they	were	 shown	 to	have	
lower values of Kcat/Km (Kcat/Km = 0.0062 μM−1 s−1	for	NfnB-his).	
The lower Km values produced when using XenB-his and XenB-
cys	compared	 to	NfnB-his	 is	a	 result	of	clinical	 significance	as	 the	
maximum tolerated dose of CB1954 in humans is less than 10 μM 
CB1954 (Chung-Faye et al., 2001); therefore, enzymes that operate 
better at lower prodrug concentrations are likely to be viable in a 
clinical setting.
3.4  |  HPLC analysis
Following the method previously published (Ball et al., 2019; Gwenin 
et	al.,	2015),	the	ratio	of	the	CB1954	NHOH	derivatives	formed	after	
the reduction of the CB1954 prodrug by either XenB-his or XenB-
cys (Figure 2) was analyzed and these ratios are presented in Table 3.
The hydroxylamine product ratios produced for XenB-his (3:97) 
and XenB-cys (6:94) were both extremely similar to one another, and 
in both cases, the enzyme demonstrated a preference for reducing 
CB1954	at	the	4-position	to	give	the	4-NHOH	as	the	major	product	
of	the	reaction.	This	is	a	result	of	clinical	significance	as	the	4-NHOH	
derivative of CB1954 has been shown in the literature to be fur-
ther	reduced	by	intracellular	thioesters	such	as	Acetyl	Coenzyme	A	
to	form	a	compound	that	can	cross-link	DNA	(Anlezark	et	al.,	1992;	
Knox et al., 1991; Race et al., 2007).
3.5  |  Cell viability assays
Percentage cell viability of SK-OV-3 cells, relative to untreated con-
trols, was determined in the presence of increasing concentrations 
of either XenB-his or XenB-cys enzyme, with a constant concentra-
tion of CB1954 present (Figure 3). Controls were cell culture medium 
only, the enzyme only and prodrug only and data points were plot-
ted based on the averages taken from at least three repeats. The 
CB1954 concentration used was fixed at 10 µM so that the results 
of the cell viability assays could be related to clinical results, because 
the CB1954 concentration in vivo cannot exceed 10 µM due to the 
maximum tolerated dose observed in clinical trials thus far (Chung-
Faye	et	 al.,	 2001;	McNeish	et	 al.,	 1998;	 Searle	 et	 al.,	 1998,	2004;	
Williams et al., 2015).
Promisingly, no cell kill was observed when cells were treated 
with the controls of CB1954 or enzyme. Upon the addition of 25 nM 
enzyme, both for XenB-his and XenB-cys, there was an immedi-
ate response in terms of cell viability percentage with an observed 
cell	 kill	 of	 roughly	25%–30%.	As	 there	was	no	added	NADPH	co-
factor present in the cell viability assay, it is of promise that such 
a significant cell kill indicated that the enzymes, free in solution, 
were taken up into the SK-OV-3 cells. It was noticeable that there 
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occurred an initial decrease in the cell-killing potency of treatments 
as the enzyme concentration was increased from 25 nM before the 
cell-killing potency began to increase again as the enzyme concen-
tration approached 200 nM. While this may initially appear to be an 
F I G U R E  1   UV/Vis spectra showing the enzymatic reduction of CB1954 to its hydroxylamine derivatives (λmax = 420 nm) by XenB-his in 










XenB-his 5.9 1690 8.2 0.0049
XenB-cys 2.5 457 1.8 0.0039
NfnB-his 22.9 4064 25.1 0.0062
Note: Previously	published	data	for	NfnB-his	have	also	been	shown	for	comparison	to	XenB-his	and	
XenB-cys (Ball et al., 2019).
TA B L E  2   The Michaelis–Menten 
kinetic data obtained for XenB-his and 
XenB-cys (10 µg/ml) by varying the 
concentrations of the CB1954 prodrug in 
the	presence	of	NADPH	as	the	cofactor
F I G U R E  2  HPLC	chromatogram	of	the	reaction	between	CB1954	and	either	XenB-his	or	XenB-cys,	measuring	absorbance	at	420	nm.	
NADPH	and	phosphate	buffer	were	detected	at	2–4	min,	unreacted	CB1954	prodrug	was	detected	at	10.5–14	min	and	DMSO	was	detected	
at 22.5–24.5 min. The 4-hydroxylamine was detected at 5–6 min and the corresponding amine was detected at 14.5–15.5 min. The 
2-hydroxylamine was detected at 9–10 min with the corresponding amine being detected at 21–22 min
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unexpected result, it is a known phenomenon called the Hormetic 
effect, which has been well documented in the literature (Mattson, 
2008). The Hormetic effect is evident in the biphasic response of 
the SK-OV-3 cells to the increasing amounts of enzyme used in 
the treatments, leading to the characteristic inverted U-shaped re-
sponse	on	the	graph	(Mattson,	2008).	Also	seen	from	Figure	3	was	
that neither enzyme nor the CB1954 prodrug alone could cause sig-
nificant cell death.
4  |  DISCUSSION
The major aim of this research was to clone and express genetically 
modified Xenobiotic reductases from P. putida and assess their ability 
to reduce the CB1954 prodrug and demonstrate an ability to cause 
cell death in the ovarian cancer cell line, SK-OV-3. It is of signifi-
cance that these enzymes have never before been reacted with the 
Cb1954 prodrug, and it was hoped that the results obtained would 
show the recombinant enzymes to be suitable candidates for use 
in	the	novel-directed	enzyme	prodrug	therapy	approach,	MNDEPT	
(Gwenin, Gwenin, & Kalaji, 2009; Gwenin et al., 2011). To achieve 
the aims, it was determined whether or not the enzymes could (a) 
effectively reduce CB1954 at low prodrug concentrations, (b) had a 
preference	for	reducing	the	prodrug	at	the	4-NO2 position instead 
of	the	2-NO2 position, and (c) cause cell death in Sk-OV-3 ovarian 
cancer cells when reacted with the prodrug.
All	of	the	aims	were	achieved	and	XenB-cys	identified	as	a	prom-
ising	candidate	for	MNDEPT.	Despite	the	poor	activity	of	XenA-his	
leading to this enzyme being dropped from the study, XenB-his and 
subsequently XenB-cys have been shown to reduce the CB1954 
prodrug. Both proteins showed a preference for reduction at the 
more	desirable	4-NO2 position and induced increased cell death in 
the ovarian cancer cell line SK-OV-3.
The fact that XenB-his and XenB-cys were shown to reduce 
CB1954	almost	exclusively	at	the	4-NO2 position was a significant 
result	because	intracellularly	the	4-NHOH	derivative	of	CB1954	is	
further	reduced	by	thioesters	to	a	DNA	crosslinking	species	which	
is	 highly	 cytotoxic	 (Anlezark	 et	 al.,	 1992).	 It	 has	 been	 shown	pre-
viously by Ball et al. (2019) that the hydroxylamine product ratio 
produced after the reduction of the CB1954 prodrug changes over 
time	 in	 favor	 of	 the	 4-NHOH	product	 as	 the	 2-NHOH	product	 is	
more rapidly converted via a non-enzymatic reduction into the cor-
responding	amine	(2-NH2)	than	the	4-NHOH	product.	In	the	case	of	
XenB-his	and	XenB-cys,	a	negligible	amount	of	2-NH2 was obtained, 
which indicated that little-to-no 2-hydroxylamine had been formed 
and that both proteins reduced CB1954 almost exclusively at the 
4-NHOH	position.	 It	 should	 be	 noted	 that	while	 reduction	 at	 the	
4-NO2 position is more favorable in terms of generating a more po-
tent	DNA-crosslinking	product,	 literature	has	suggested	that	there	
may	also	be	negatives	to	using	enzymes	that	favor	4-NO2 reduction 
over	2-NO2 reduction because of the significantly higher bystander 
effect	of	the	products	formed	after	CB1954	is	reduced	at	the	2-NO2 
position	 (Chan-Hyams,	 Copp,	 Smaill,	 Patterson,	&	Ackerley,	 2018;	
Helsby, Ferry, Patterson, Pullen, & Wilson, 2004; Vass et al., 2009).
Upon analysis of the kinetic data obtained for XenB-his and 
XenB-cys, both proteins yielded a lower value for Km than has been 
TA B L E  3   The ratio of the CB1954 hydroxylamine derivatives 






F I G U R E  3   Percentage cell survival relative to untreated control cells of SK-OV-3 cells after a 4 h incubation with prodrug only, the 
enzyme	only	and	increasing	concentrations	of	either	XenB-his	or	XenB-cys	(25–200	nM)	in	presence	of	CB1954	(10	µM).	All	data	points	are	
taken from the averages of at least three repeats, and the error bars represent the standard deviation
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previously reported in the literature for the heavily investigated 
NfnB	NTR.	Again	this	result	is	of	clinical	significance	as	any	enzyme	
used in cancer prodrug therapy treatments in combination with 
CB1954 must be effective at lower prodrug combinations due to the 
dose-limiting toxicity of CB1954 restricting the concentration of the 
prodrug which can be used in treatments.
As	 well	 as	 characterizing	 the	 reaction	 between	 the	 Xenobiotic	
reductases, XenB-his or XenB-cys, with the CB1954 prodrug, it was 
important to ascertain if the enzyme/prodrug combinations could 
cause cell death in a cancerous cell line, in this case, the ovarian cancer 
cell line SK-OV-3. It was decided that the cancer cell kill experiments 
would be carried out without the addition of extracellular cofactor 
so that any cell-killing observed could be attributed to the success-
ful uptake of the enzymes into the cancer cells, thus accessing the 
intracellular cofactor. The results obtained for the 2D cell culture ex-
periments confirmed that XenB-his and XenB-cys were successfully 
taken up into SK-OV-3 cells and induced cell death after reducing the 
CB1954 prodrug to its toxic products, thus identifying them as prom-
ising enzymes for use in cancer prodrug therapy treatments.
In conclusion, two Xenobiotic reductases were identified, cloned, 
expressed, and tested with the CB1954 prodrug. Unfortunately, the 
XenA-his	reductase	was	shown	not	to	reduce	the	CB1954	prodrug	at	
detectable levels, even though it was capable of reducing nitro-glyc-
erin. Together with other literature, it was thus hypothesized that 
this enzyme was unable to reduce nitroaromatic compounds. XenB-
his and subsequently XenB-cys were shown to be able to readily re-
duce	CB1954,	primarily	at	the	4-NO2 position, and these enzyme/
prodrug combinations were shown to cause significant cell death 
in SK-OV-3 cells without the addition of extracellular cofactor thus 
confirming they are promising candidates for use in DEPT strate-
gies. The next stage of this research will be to assess the XenB-cys 
enzyme when immobilized onto gold-coated magnetic nanoparticles 
(AuMNPs)	to	see	if	this	leads	to	any	loss	of	activity	with	the	CB1954	
prodrug or a change in the performance in cell viability assays.
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APPENDIX A
F I G U R E  A 1   SDS-PAGE	of	the	purifications	of	(a)	XenA-his,	
(b) XenB-his and (c) XenB-cys. Flowthrough (FT) 1 and 2 were the 
first	eluted	fractions	collected	after	adding	the	protein	to	the	IMAC	
column. Imidazole concentration was then steadily increased from 
50 mM to 800 mM to elute the pure his-tagged proteins
(a)
(b)
(c)
